Skip to main content
Premium Trial:

Request an Annual Quote

LifeCodexx Begins Clinical Validation Study of Sequencing-Based T21 Test

Premium

With a pilot study complete, scientists from GATC Biotech subsidiary LifeCodexx have started the clinical validation study of a sequencing-based trisomy 21 test, which it plans to launch by the end of the year.

The company will conduct the clinical validation study on 500 samples in conjunction with several European prenatal centers on the Illumina HiSeq 2000. In a statement, CEO Michael Lutz said the researchers would pool up to seven samples, which would help cut costs by 50 percent.

In the pilot study, completed this past April, the researchers tested their assay on 45 patients (CSN 4/19/2011). While the company has not published the results of the pilot test or disclosed details on its methodology, according to Lutz, the test achieved 100 percent sensitivity and specificity, and is very similar to the method that Sequenom is basing its trisomy 21 test on.

The LifeCodexx test will be launched in Europe as a lab-developed test, and Lutz has previously said that it has no plans to market its test in the US. Sequenom and Verinata Health are also both planning to launch trisomy 21 tests as LDTs by the end of this year or early next year (CSN 5/4/2011), and Sequenom is planning to file for pre-market approval from the US Food and Drug Administration by the end of 2012 (CSN 6/15/2011).

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.